Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

The adhesion molecule ICAM-1 is overexpressed in patients with Hymenoptera venom allergy and decreases after ultrarush venom immunotherapy.

Patella V, Incorvaia C, Ricciardi L, Florio G, Saija A, Frati F, Gangemi S.

J Biol Regul Homeost Agents. 2011 Jul-Sep;25(3):465-8.

PMID:
22023772
2.

Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety.

Müller U, Helbling A, Berchtold E.

J Allergy Clin Immunol. 1992 Feb;89(2):529-35.

PMID:
1740583
3.

Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.

Pereira Santos MC, Pedro E, Spínola Santos A, Branco Ferreira M, Palma Carlos ML, Palma Carlos AG.

Eur Ann Allergy Clin Immunol. 2005 Sep;37(7):273-8.

PMID:
16285233
4.

Agreement of skin test with IL-4 production and CD40L expression by T cells upon immunotherapy of subjects with systemic reactions to Hymenoptera stings.

Urra JM, Cabrera CM, Alfaya T, Feo-Brito F.

Mol Immunol. 2016 Feb;70:134-9. doi: 10.1016/j.molimm.2015.12.013. Epub 2016 Jan 7.

PMID:
26774053
5.

Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy.

Pereira-Santos MC, Baptista AP, Melo A, Alves RR, Soares RS, Pedro E, Pereira-Barbosa M, Victorino RM, Sousa AE.

Clin Exp Allergy. 2008 Feb;38(2):291-7. Epub 2007 Dec 7.

PMID:
18070166
6.

Surface membrane antigen alteration on blood basophils in patients with Hymenoptera venom allergy under immunotherapy.

Siegmund R, Vogelsang H, Machnik A, Herrmann D.

J Allergy Clin Immunol. 2000 Dec;106(6):1190-5.

PMID:
11112905
7.
8.

Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients.

Sturm G, Kränke B, Rudolph C, Aberer W.

J Allergy Clin Immunol. 2002 Dec;110(6):928-33.

PMID:
12464961
9.

Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects.

Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J.

Eur J Immunol. 1997 May;27(5):1131-9.

PMID:
9174602
10.

Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings.

Ewan PW, Deighton J, Wilson AB, Lachmann PJ.

Clin Exp Allergy. 1993 Aug;23(8):647-60.

PMID:
8221268
11.

Wasp venom immunotherapy induces a shift from IL-4-producing towards interferon-gamma-producing CD4+ and CD8+ T lymphocytes.

Schuerwegh AJ, De Clerck LS, Bridts CH, Stevens WJ.

Clin Exp Allergy. 2001 May;31(5):740-6.

PMID:
11422133
12.
13.

Safety of Ultrarush Venom Immunotherapy: Comparison Between Children and Adults.

Nittner-Marszalska M, Cichocka-Jarosz E, Małaczyńska T, Kraluk B, Rosiek-Biegus M, Kosinska M, Pawłowicz R, Lis G.

J Investig Allergol Clin Immunol. 2016;26(1):40-7.

14.

Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors.

Birnbaum J, Ramadour M, Magnan A, Vervloet D.

Clin Exp Allergy. 2003 Jan;33(1):58-64.

PMID:
12534550
15.

Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients.

Wenzel J, Meissner-Kraemer M, Bauer R, Bieber T, Gerdsen R.

Allergy. 2003 Nov;58(11):1176-9.

16.

Specific ultrarush desensitization in Hymenoptera venom-allergic patients.

Schiavino D, Nucera E, Pollastrini E, De Pasquale T, Buonomo A, Bartolozzi F, Lombardo C, Roncallo C, Patriarca G.

Ann Allergy Asthma Immunol. 2004 Apr;92(4):409-13.

PMID:
15104191
17.

Mechanisms of immunotherapy to wasp and bee venom.

Ozdemir C, Kucuksezer UC, Akdis M, Akdis CA.

Clin Exp Allergy. 2011 Sep;41(9):1226-34. doi: 10.1111/j.1365-2222.2011.03812.x. Epub 2011 Jul 5. Review.

PMID:
21729181
19.
20.

Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.

Goldberg A, Yogev A, Confino-Cohen R.

Int Arch Allergy Immunol. 2011;156(1):90-8. doi: 10.1159/000322258. Epub 2011 Mar 30.

PMID:
21447964

Supplemental Content

Support Center